IBM and Pfizer to accelerate immuno-oncology research with Watson for Drug Discovery
- Details
- Category: Pfizer
IBM (NYSE: IBM) Watson Health and Pfizer Inc. (NYSE: PFE) have announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's research in immuno-oncology, an approach to cancer treatment that uses the body's immune system to help fight cancer.
Takeda to invest more than 100 million Euros in dengue vaccine manufacturing plant in Germany
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited (TOKYO:4502) ("Takeda") has announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany. This represents a major step by Takeda toward meeting important unmet needs in dengue prevention. According to the World Health Organization (WHO), dengue is the fastest spreading mosquito-borne viral disease.
Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and China Southeast University Institute of Life Sciences have announced the start of a joint research project to develop new treatment approaches for hearing loss through regeneration of hair cells from inner ear stem cells. The new collaboration combines the expertise of Professor Renjie Chai, one of the worldwide leaders in the field of hearing loss,
AstraZeneca takes latest scientific advances in oncology to major US and European congresses
- Details
- Category: AstraZeneca
AstraZeneca and its global biologics research and development arm, MedImmune, will continue the oncology momentum built during 2016 with a strong end-of-year presence at three major congresses. In total, 50 abstracts - including 15 oral presentations - have been accepted across:
GSK Announces EU Regulatory Submission of Candidate Vaccine for Prevention of Shingles
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) has announced the regulatory submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval for its candidate shingles vaccine, ShingrixTM, for the prevention of herpes zoster (shingles) in people aged 50 years or over.
Lilly announces top-line results of solanezumab phase 3 clinical trial
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) today announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
Shire to establish rare disease innovation hub in Cambridge, Mass.
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPG) has announced that it will expand its operations in Cambridge, Massachusetts, establishing a rare disease innovation hub and increasing its footprint in the heart of Kendall Square. Shire and BioMed Realty have signed a lease for a 343,000-square-foot building at 500 Kendall Street. Shire’s lease begins in Q3, 2018, with occupancy anticipated for Q1, 2019.
More Pharma News ...
- Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
- Roche launches imCORE, a global network of cancer immunotherapy centers of excellence
- Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study
- Novo Nordisk expands programme to reach 20,000 children with diabetes in developing countries
- Merck wins R&D 100 Award for top invention
- Regorafenib from Bayer submitted to health authorities seeking approval in second-line treatment of liver cancer
- New European study highlights differing priorities in physician's therapy goals when treating advanced lung cancer patients